AtriCure (ATRC) Stock Forecast & Price Target

AtriCure is supported by a differentiated, category-leading franchise in surgical Afib, LAA management, and pain management, with the latter emerging as a key growth engine at +27% y/y in 1H26 and expected to drive low-teens overall revenue growth. Its financial trajectory looks improving as estimates call for FY27 and FY28 revenue of $680 mln and $765 mln, with adjusted EBITDA of $100 mln and $120 mln, implying roughly 300-400 bps of margin expansion versus FY25 and stronger free cash flow conversion. The outlook is further reinforced by multiple catalysts, including cryoXT and cryoSPHERE MAX in pain management, the STS quality metric, and BoxX-NoAF and LeAAPS, which together could expand the addressable market and sustain mid-teens growth through the end of the decade.

AtriCure is facing a negative outlook because its growth depends on widespread physician adoption, but competition, training constraints, and shifting reimbursement policies could slow market acceptance and pressure market share. The company also carries meaningful clinical and regulatory risk, since future data may not be positive and current or planned trials may fail to meet FDA or other authority requirements. Although the stock has more than doubled from its lows in early June 2026 and now trades at a peer-group-high ~25x 2027E EBITDA, that valuation already appears to discount positive BoxX-NoAF POAF data and mid-term margin expansion, leaving limited room for disappointment.